Health economics in haemophilia: a review from the clinician's perspective

Health economic evaluations provide valuable information for healthcare providers, facilitating the treatment decision‐making process in a climate where demand for healthcare exceeds the supply. Although an uncommon disease, haemophilia is a life‐long condition that places a considerable burden on patients, healthcare systems and society. This burden is particularly large for patients with haemophilia with inhibitors, who can develop serious bleeding complications unresponsive to standard factor replacement therapies. Hence, bleeding episodes in these patients are treated with bypassing agents such as recombinant activated FVII (rFVIIa) and plasma‐derived activated prothrombin complex concentrates (pd‐APCC). With the efficacy of these agents now well established, a number of health economic studies have been conducted to compare their cost‐effectiveness for the on‐demand treatment of bleeding episodes in haemophiliacs with inhibitors. In a cost‐utility analysis, which assesses the effects of treatment on quality of life (QoL) and quantity of life, the incremental cost per quality‐adjusted life‐year (QALY) gained (US $44 834) indicated that rFVIIa was cost‐effective. Similarly, eight of 11 other economic modelling evaluations found that rFVIIa was more cost‐effective than pd‐APCC in the on‐demand treatment of bleeding episodes. These findings indicate that treating patients with haemophilia promptly and with the most effective therapy available may result in cost savings.